Dexamethasone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Dexacort

Dexamethasone is a synthetic member of the glucocorticoid class of hormones. It acts as an anti-inflammatory and immunosuppressant. Its potency is about 40 times that of hydrocortisone. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Therapeutic use

Dexamethasone is used to treat many inflammatory and autoimmune conditions, e.g., rheumatoid arthritis. It is also given to cancer patients undergoing chemotherapy, to counteract certain side-effects of their antitumor treatment. Dexamethasone can augment the antiemetic effect of 5-HT3 receptor antagonists like ondansetron.

In brain tumours (primary or metastatic), dexamethasone is used to counteract the development of edema, which could eventually compress other brain structures. Dexamethasone is also given in cord compression where tumor is compressing the spinal cord.

Dexamethasone is also used in certain hematological malignancies, especially in the treatment of multiple myeloma, in which dexamethasone is given alone or together with thalidomide (thal-dex) or a combination of Adriamycin and vincristine (VAD).

It is useful to counteract allergic shock, if given in high doses. It is present in certain eye drops and as a nasal spray (Dexacort®).

Diagnostic use

Dexamethasone is also used in a diagnostic context, namely in its property to suppress the natural pituitary-adrenal axis. Patients presenting with clinical signs of glucocorticoid excess (Cushing's syndrome) are generally diagnosed by a 24-hour urine collection for cortisol or by a dexamethasone suppression test. During the latter, the response of the body to a high dose of glucocorticoids is monitored. Various forms are performed. In the most common form, a patient takes a nightime dose of either 1 or 4 mg of dexamethasone, and the serum cortisol levels are measured in the morning. If the levels are relatively high (over 5 μg/dl or 150 nmol/l), then the test is positive and the patient has an autonomous source of either cortisol or ACTH, indicating Cushing's syndrome. Longer versions rely on urine collections on oral dexamethasone over various days.

Contraindications

Some of these contraindications are relative:

  • Existing gastrointestinal ulceration
  • Cushing's syndrome
  • Severe forms of heart insufficiency
  • Severe hypertension
  • Uncontrolled diabetes mellitus
  • Systemic tuberculosis
  • Severe systemic viral, bacterial, and fungal infections
  • Preexisting wide angle glaucoma
  • Osteoporosis

Side effects

If dexamethasone is given orally or by injection (parenteral) over a period of more than a few days, side-effects common to systemic glucocorticoids may occur. These may include:

  • Stomach upset, increased sensitivity to stomach acid to the point of ulceration of esophagus, stomach, and duodenum
  • Increased appetite leading to significant weight gain
  • A latent diabetes mellitus often becomes manifest. Glucose intolerance is worsened in patients with preexisting diabetes.
  • Immunsuppressant action, particular if given together with other immunosuppressants such as ciclosporine. Bacterial, viral, and fungal disease may progress more easily and can become life-threatening. Fever as a warning symptom is often suppressed.
  • Psychiatric disturbances, including personality changes, irritability, euphoria, mania
  • Osteoporosis under long term treatment, pathologic fractures (e.g., hip)
  • Muscle atrophy, negative protein balance (catabolism)
  • Elevated liver enzymes, fatty liver degeneration (usually reversible)
  • Cushingoid (syndrome resembling hyperactive adrenal cortex with increase in adiposity, hypertension, bone demineralization, etc.)
  • Depression of the adrenal gland is usually seen, if more than 1.5 mg daily are given for more than three weeks to a month.
  • Hypertension, fluid and sodium retention, edema, worsening of heart insufficiency (due to mineral corticoid activity)
  • Dependence with withdrawal syndrome is frequently seen.
  • Increased intraocular pressure, certain types of glaucoma, cataract (serious clouding of eye lenses)
  • Dermatologic: Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound-healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.
  • Allergic reactions (though infrequently): Anaphylactoid reaction, anaphylaxis, angioedema. (Highly unlikely, since dexamethasone is given to prevent anaphylactoid reactions.)

Other side-effects have been noted. Ask your doctor, if you notice them and if they are more than mild.

Read more at Wikipedia.org


[List your site here Free!]


Medeva comes back from the cold with 35% boost
From Independent, The (London), 3/15/95 by MAGNUS GRIMOND

Medeva, the pharmaceuticals group that fell from grace after a profits warning in 1993, went a long way to restoring its reputation after announcing better than expected results yesterday.

The shares jumped 15p to 196p after the group revealed a 35 per cent leap in pre-tax profits to pounds 64.2m for the year to December.

The group, which took on new management a little over a year ago, has been struggling to shed its reputation for being driven by deals rather than organic growth. Bernard Taylor, chairman, said 1994 had been a very successful year in accomplishing Medeva's strategy of buying "late- stage" development projects.

He announced the go-ahead for further trials of Hepagene, a vaccine against hepatitis B, which he said "has the potential to transform the group".

According to Bill Bogie, the chief executive who arrived last year, the market for Hepagene is big, covering around 10 million people worldwide. He dismissed problems faced by Medeva over patents with Hepagene in the US.

The company is also very excited about the prospects for its new albuterol metered-dose inhaler for the treatment of asthma and similar conditions. The new product could be ready to attack a pounds 400m market in 1996 if US approvals are received this year.

But analysts believe the shares will struggle to break through the 200p barrier while another deal could be in the pipeline.

Mr Taylor was enigmatic on the subject yesterday, although with net cash balances up to pounds 14m at the year-end the company said it could raise debt finance of over pounds 100m to further its growth. He also said that the recent blockbuster mergers in the industry could spell good news for the company.

Last year's acquisitions - Burroughs Wellcome's Semprex-D antihistamine, Merck's Dexacort inhaled products and Inhalon, with its two anaesthetics - added just 0.5 percentage points to sales up 20 per cent to pounds 240m.

Fully-diluted earnings per share leapt from 11.4p to 13.8p, out of which Medeva is paying a final dividend of 2.2p to raise the total for the year from 2.7p to 3.3p.

Most of the company's growth last year came on the back of its sinister- sounding "attention deficit disorder" drug, methylphenidate.

Sales soared 89 per cent to pounds 66m, against a more pedestrian 7 per cent on average for Medeva's other nine leading products.

Dr Bogie insists that methylphenidate - used to tame disruptive schoolchildren or those who find difficulty concentrating on lessons - treats a genuine medical condition. Its use has expanded by 30 per cent a year over the last four.

Paul Diggle, at the broker Societe General Strauss Turnbull, believes profits from the drug could reach pounds 76.5m this year.

Copyright 1995 Newspaper Publishing PLC
Provided by ProQuest Information and Learning Company. All rights Reserved.

Return to Dexacort
Home Contact Resources Exchange Links ebay